Abl Kinase Regulation by BRAF/ERK and Cooperation with Akt in Melanoma

The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring BRAF(V600E) and PTEN mutations often are resistant to current therapies, including BRAF inhibitors (BRAFi)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Aditi, Tripathi, Rakshamani, Turpin, Courtney P., Wang, Chi, Plattner, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552414/
https://www.ncbi.nlm.nih.gov/pubmed/28368422
http://dx.doi.org/10.1038/onc.2017.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552414/
https://www.ncbi.nlm.nih.gov/pubmed/28368422
http://dx.doi.org/10.1038/onc.2017.76

Ejemplares similares